Free Trial
NASDAQ:OCS

Oculis Q1 2025 Earnings Report

Oculis logo
$19.28 -0.20 (-1.03%)
Closing price 06/20/2025 04:00 PM Eastern
Extended Trading
$19.17 -0.11 (-0.57%)
As of 06/20/2025 04:15 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Oculis EPS Results

Actual EPS
-$0.77
Consensus EPS
-$0.51
Beat/Miss
Missed by -$0.26
One Year Ago EPS
N/A

Oculis Revenue Results

Actual Revenue
$0.32 million
Expected Revenue
$0.22 million
Beat/Miss
Beat by +$100.00 thousand
YoY Revenue Growth
N/A

Oculis Announcement Details

Quarter
Q1 2025
Time
Before Market Opens
Conference Call Date
Thursday, May 8, 2025
Conference Call Time
4:00PM ET

Upcoming Earnings

Oculis' Q2 2025 earnings is scheduled for Tuesday, August 26, 2025

Earnings Documents

Oculis Earnings Headlines

The DOJ Just Paved the Way for Account Seizures
Washington is running out of money…And guess where they'll look next? When governments go broke, they take from the people. It's happened before, and it's happening again. The Department of Justice just admitted that cash isn't legally YOUR property.
Oculis to Participate in Upcoming June Investor Conferences
See More Oculis Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Oculis? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Oculis and other key companies, straight to your email.

About Oculis

Oculis (NASDAQ:OCS), a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic diseases. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis. The company is based in Zug, Switzerland.

View Oculis Profile

More Earnings Resources from MarketBeat